Currently Viewing:
AMCP 2017
Analyzing the Near-Term Pipeline for Specialty Drugs
March 28, 2017
Dr Aimee Tharaldson Highlights Two Key Drugs for 2017
March 28, 2017
Effectively Moving Toward Value-Based Care
March 28, 2017
Susan A. Cantrell on the Evolution of Value Frameworks
March 28, 2017
Dr Liz Zhou Explains Basal Insulin Switching Study on Toujeo
March 28, 2017
Dr Richard Willke on Using Real-World Data to Inform Value-Based Contracts
March 29, 2017
The Unsustainably Big Business of Healthcare
March 29, 2017
Currently Reading
Dr Matthew Pickering: How Quality Measures Are Created and Implemented
March 29, 2017
Dr Clifford Goodman Outlines Takeaways From a Health Economic Case Study on Repatha
March 30, 2017
Dr Doug Hillblom on the State of e-Prescribing and Remaining Barriers
March 30, 2017
Cardiovascular Outcome Trials: How Misinterpretation of Statistics Can Affect Clinical Practice
March 30, 2017
Repatha Offers Additional LDL-C Reduction in a Convenient Dosage Form
March 30, 2017
ACA Repeal and Other Healthcare Issues on the Trump Administration's Agenda
April 03, 2017
The Latest in the Move to Value-Based Reimbursement and Remaining Challenges
April 04, 2017
Susan Cantrell: Uncertainty Is Affecting Everyone in Healthcare
April 11, 2017
Dr Aimee Tharaldson Discusses 2 New Treatments for Tardive Dyskinesia
April 12, 2017
Dr Gail Bridges Explains the High Real-World Cure Rate for HCV
April 17, 2017
Dr Richard Willke Previews ISPOR 2017 in Boston
April 18, 2017
Dr Matthew Pickering Discusses Development, Implementation of Quality Measures
April 20, 2017
Dr Doug Hillblom Expects Evolution of e-Prescribing to Continue
April 22, 2017
Dr Aimee Tharaldson: We're Keeping an Eye on Future NASH Treatments
April 27, 2017
Susan A. Cantrell Outlines Concerns and Opportunities for Managed Care
May 01, 2017
The Importance of Ethical Committees in the Evolving Healthcare Environment
May 11, 2017
Dr Lou Garrison on the Discussions Surrounding Outcomes-Based Arrangements
May 17, 2017

Dr Matthew Pickering: How Quality Measures Are Created and Implemented

The creation and implementation of a new quality measure is a long process that includes considering other measures on the market, actually developing the measure and, ultimately, testing its scientific acceptability, explained Matthew Pickering, PharmD, RPh, associate director of research and quality strategies at the Pharmacy Quality Alliance.


The creation and implementation of a new quality measure is a long process that includes considering other measures on the market, actually developing the measure and, ultimately, testing its scientific acceptability, explained Matthew Pickering, PharmD, RPh, associate director of research and quality strategies at the Pharmacy Quality Alliance.

What is the process of getting a newly created measure implemented?

The process originally starts out with developing a measure concept. Before it even moves on to the development phase overall, it starts out as a measure concept, and that measure concept starts with a gap analysis to see where gaps exist in healthcare, to where we can develop a measure to actually fill those gaps. Those gaps could be from evidence that comes out, like clinical practice guidelines, noting that we need to have a patient on a certain medication because we know that sound evidence has told us this.

Once a concept has been developed, we also need to consider what other measures are out there in the market that are along the same lines of this measure concept. If there’s another measure, we don’t necessarily want to create a duplicative measure. It is a harmonization that can happen, of the measure specifications that are already in existence.

After the measure concept is there, it moves on to development. This is where we convene experts from the clinical side and also the technical side to really define the measure specifications. What do our eligible populations look like for the measure? What do our exclusions look like? What’s the numerator, ultimately? What are the data sources that are most appropriate to actually capture the measure concept? And also, what’s the level of accountability? Who are we holding accountable? Is it health plans or providers, individual physicians, et cetera?

Once the measure’s been fully developed, it needs to be tested. It needs to be tested for its scientific acceptability, so is it valid, is it reliable? Also, is it feasible? If it upholds against those criteria, it can then move forward to endorsement. Which, there’s other criteria to consider as well. How is it going to be used? What’s the usability of the measure? Is it really important and impactful to health care? Then, if it passes that, it gets that golden seal of approval of endorsement, and it can then be implemented.

So it’s a long process, and it’s very time-intensive, but it’s needed to develop a good quality measure.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!